心血管影像在接受心脏毒性治疗肿瘤患者中的作用:欧洲心脏病学会心力衰竭协会、欧洲心血管影像协会及心脏肿瘤委员会立场声明
该立场声明由欧洲心脏病学会心力衰竭协会影像与心脏肿瘤学组联合欧洲心血管影像协会及心脏肿瘤委员会制定,评估超声心动图、心脏磁共振、核心脏成像和计算机断层扫描在肿瘤患者管理中的价值,提出基线评估及针对蒽环类化疗、HER2靶向治疗等特定治疗的监测路径,并讨论放疗远期识别、特殊人群和未来研究方向。
要点
- 推荐采用整体纵向应变和三维射血分数等超声心动图参数用于肿瘤治疗相关心血管损伤的评估。
- 声明提出了蒽环类化疗、HER2靶向治疗、VEGF酪氨酸激酶抑制剂等治疗前基线评估和特定监测路径。
- 放疗的典型后果及其长期识别可能性被总结,特殊人群包括计划妊娠的女性幸存者、类癌疾病患者等。
核心结论
- 心血管影像在接收心脏毒性肿瘤治疗患者的基线风险评估和心血管疾病检测中具有重要价值。
研究设计与样本
- 该文件为欧洲心脏病学会心力衰竭协会影像与心脏肿瘤学组联合欧洲心血管影像协会及欧洲心脏病学会心脏肿瘤委员会制定的立场声明,基于对当前证据的评估,未报告系统检索方法、样本量或证据分级。
诊断标准与关键数值
- 声明提出最相关的超声心动图参数包括整体纵向应变和三维射血分数。
- 声明提出了蒽环类化疗、HER2靶向治疗(如曲妥珠单抗)、血管内皮生长因子酪氨酸激酶抑制剂、BCr-Abl酪氨酸激酶抑制剂、蛋白酶体抑制剂和免疫检查点抑制剂的基线治疗前评估方案及特定监测算法或路径。
- 声明考虑了肿瘤治疗完成后的心血管影像适应证。
临床应用与阅片要点
- 声明建议在肿瘤治疗前进行基线心血管影像评估,并针对不同心脏毒性治疗采用特定的监测算法或路径。
- 声明总结了放疗的典型后果及其长期识别的可能性。
- 声明讨论了特殊人群,包括计划妊娠的女性幸存者、类癌疾病患者、心脏肿瘤患者和右心衰竭患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position statement examines the role of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging and computed tomography in the management of cancer patients. The Imaging and Cardio-Oncology Study Groups of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the ESC have evaluated the current evidence for the value of modern CV imaging in the cardio-oncology field. The most relevant echocardiographic parameters, including global longitudinal strain and three-dimensional ejection fraction, are proposed. The protocol for baseline pre-treatment evaluation and specific surveillance algorithms or pathways for anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor tyrosine kinase inhibitors, BCr-Abl tyrosine kinase inhibitors, proteasome inhibitors and immune checkpoint inhibitors are presented. The indications for CV imaging after completion of oncology treatment are considered. The typical consequences of radiation therapy and the possibility of their identification in the long term are also summarized. Special populations are discussed including female survivors planning pregnancy, patients with carcinoid disease, patients with cardiac tumours and patients with right heart failure. Future directions and ongoing CV imaging research in cardio-oncology are discussed.
引用
- Čelutkienė J, Pudil R, López-Fernández T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020. PMID: 32621569. doi:10.1002/ejhf.1957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。